

www.epa.gov

In Vitro Characterization of Oral Absorption of Non-Pharmaceutical Chemicals

¹National Center for Computational Toxicology, U.S. EPA, Research Triangle Park, NC; ²Oak Ridge Institute for Science and Education, Oak Ridge, TN; ³Cyprotex US LLC, Watertown, MA

Background

- Data from high throughput *in vitro* screening assays describe potential **hazard**.
- **Toxicokinetics** may be used to determine corresponding oral equivalent doses for comparison to potential **exposure** rate (Wetmore *et al.* 2015).
- The extrapolation of *in vitro* hazard to *in vivo* oral equivalent doses may be improved by accurate definition of the **fraction absorbed** (*F*_{abs}) through the intestine
- F_{abs} are not frequently available for non-pharmaceuticals.
- The Caco-2 assay allows for measurement of an apparent permeability rate (P_{AB}) that is highly correlated with F_{abs} (Artursson *et al.* 2001)
- F_{abs} , combined with first pass hepatic clearance (F_{FP}) determined from intrinsic hepatic clearance, may be used to estimate the fraction oral bioavailability (F_{bio}).

In this work, the Caco-2 assay was run for over 400 ToxCast chemicals to measure apparent permeability and estimate fraction absorbed.

Potential improvements in toxicokinetics using more accurate estimates of F_{abs} from Caco-2 data may enable the use of *in vitro* toxicity data to inform regulatory decisions.

Methods

Experimental

- Caco-2 cells, developed from human colon carcinoma cells, form a polarized monolayer that behaves similarly to the human intestinal epithelium.
- Caco-2 cells were seeded on 96-well format plates and cultured for 20 days.
- Transepithelial electrical resistance (TEER) measurement was used to verify the formation of tight junctions between the cells and lucifer yellow, a membrane integrity marker, was co-incubated with the test compound at the start of the experiment
- Chemical stock solutions were administered in duplicate to the apical or basolateral side to measure apparent permeability from apical to basolateral (P_{AB}) or basolateral to apical (P_{BA})
- Media were collected from the receiver and donor wells 120 minutes after the addition of chemical.

Equations

area*C_{Apical}

 $F_{abs} = A_{abs} / A_{gut} \approx \text{function}(P_{AB})$

• Control chemicals of warfarin (high AB permeability control), talinolol (p-gp efflux control), and ranitidine (low AB permeability control), were measured for each monolayer batch.

dA_{Basolateral}

dt

Data analysis

- apparent permeability (P_{AB} or P_{BA}) determined by amount of compound transported per time divided by filter area and initial concentration
- *F*_{abs} calculated as a function of P_{AB}
- *F_{FP}* determined using previously measured values for intrinsic clearance and fraction unbound (Pearce et *al.* 2017)

$$F_{FP} \approx \frac{Q_{liv}}{Q_{liv} + f_{up}Cl/R_{b2p}}$$

$$\mathbf{F}_{bio} = \mathbf{F}_{abs} \mathbf{F}_{FP}$$

(assume $F_{abs,rat} = F_{abs,human}$)





U.S. Environmental Protection Agency Office of Research and Development

 $P_{AB} = -$

Disclaimer: The views expressed in this poster are those of the authors and do not necessarily represent the views or policies of the U.S. Environmental Protection Agency

G. S. Honda^{1,2}, C. Strock³, D. Angus³, R. Dinallo³, R. G. Pearce^{1,2}, R. S. Thomas¹, and J. F. Wambaugh¹

absorptive surface area: $S = 200 m^2$ intestinal transit rate: $k_i = 5 * 10^{-3} min^{-1}$ volume of distribution (V_d) determined using *httk* (limited to chemicals with $f_{\mu\nu}$ measured in vitro)

Gregory Honda I honda.gregory@epa.gov I orcid: 0000-0001-7713-9850

Predicted vs measured values of F_{abs} and F_{bio}

- Literature values for measured F_{abs} mostly for pharmaceuticals (from *httk* R package, multiple sources)
- Darwich provides better estimates of F_{abs} for this set of chemicals
- Median values of $F_{abs. calculated}$ with error bars (±2 std. dev.) for controls of ranitidine and warfarin



F_{bio} rat calculated vs literature measured value

- **F**_{bio} measured in vivo rat data from Wambaugh et al. 2018
- GastroPlus *F*_{bio} determined *in silico*, otherwise $F_{bio} = F_{abs}F_{FP}$ based on in *vitro* results
- Usansky gives the best result
- **F**_{FP}:
- Restrictive clearance assumed
- Nonrestrictive clearance would result in lower F_{bio}



Influence of F_{bio} on prediction of toxicokinetics



- observed for this limited set of chemicals

Summary

- P_{AB} was measured for 274 ToxCast chemicals
- While 87% of chemicals are estimated to be highly absorbed ($F_{abs} \ge 0.80$), the remainder of chemicals have significantly lower F_{abs} (median of 0.49)
- F_{abs} predicted using measured P_{AB} was highly correlated with literature values
- F_{bio} was poorly correlated with measured values reported in literature; different assumptions in hepatic clearance (restrictive vs. nonrestrictive) may influence estimates for F_{bio} References:

Artursson et al. Adv. Drug Deliv. Rev. 2001, 46, 27-43 Darwich et al. Current Drug Metabolism, 2010, 11, 716-729 Pearce, R. G. et al. J. Statistical Software. 2017, 79(4) Usansky, H.; Sinko, P. *J. Pharm. Exp. Ther.*, 2005, 314, 391-399 Wambaugh, J. F. et al. Toxicological Sciences. 2018, in press Wetmore, B. A. et al. Toxicological Sciences. 2015, 148(1), 121-136

Abstract Number: 3360 Poster Number: P142